# *Obésité et syndrome métabolique*

«le point de vue de l'endocrinologue"

PD Dr. med. Giacomo Gastaldi DiaCenTRE – Maison du Diabète – Hirslanden Grangettes SA 1224 Chêne-Bougeries





#### Mortality and Non Communicable Diseases (NCDs)









NCDs kill 41 million people each year, equivalent to 74% of all deaths globally

- Cardiovascular diseases (17,9 mio)
- Cancers (9,3 millions)
- Chronic respiratory diseases (4,1 millions)
- Diabetes Mellitus (2,0 millions)

NCD countdown Lancet 2022; 399: 1266-78

## Global population





N Engl J Med 2023; 389:1273-1285

#### Cardiovascular diseases (CVDs)

- Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs.
- It is important to detect cardiovascular disease as early as possible so that management with counselling and medicines can begin.
- Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol.



#### Metabolic syndrome

High waist circumference (WC), whose thresholds depend on populations and country-specific definitions (≥102 cm and ≥88 cm for European men and women respectively) [9];

```
•Blood TG \geq 1,7 mmol/L;
```

Blood HDL cholesterol < 1,0 mmol/L in men and <1,3 mmol/L in women;</p>

•Blood pressure (BP)  $\geq$  130/85 mmHg;

•Blood fasting glucose  $\geq$  5.6 mmol/L.

#### 3 sur 5 critères



L) in males; <50 mg/dL (1.3 m

Circulation. 2009;120(16):1640-1645.

### Obesity and DM



Page 4

Characteristic	No Diabetes (Unweighted <i>n</i> = 115 441)	Type 1 Diabetes (Unweighted $n = 733$ )	Type 2 Diabetes (Unweighted $n = 12$ 397)
Mean age, y	$46.6\pm0.1$	$49.2\pm0.9$	$62.8\pm0.2$
Age category, %			
18-44 y	$48.6\pm0.3$	$42.1\pm2.4$	$9.3\pm0.4$
45-64 y	$32.6\pm0.2$	$34.3 \pm 2.1$	$43.2\pm0.6$
≥65 y	$18.8 \pm 0.2$	$23.6 \pm 1.8$	$47.5 \pm 0.6$

Table.

Percentage of adults with overweight or obesity:

- 64% of adults without diabetes
- 62% of adults with type 1 diabetes
- 82% of adults with type 2 diabetes

Fang M et al. Ann Intern Med. 2023 March ; 176(3): 427–429.

#### Risk factors for T2D

Categories	14 Risks factors for T2D	Amount
Environmental or occupational	Ambient particulate matter pollution, household air pollution from solid fuels (PM <sub>2.5 and 10</sub> )	Incidence and prevalence of DM OR 1.2-1.4
Tobaco use	Smoking, second-hand smoke	> 20 cig/day OR 1.55-1.9 (men) OR 1.47 (women)
Alcool use	High alcohol use	60g/day (men) 50g/day (women)
Body fat	BMI (body-mass index)	OR 1.5 (BMI 24kg/m2) (men) OR 2.9 (BMI 23kg/m2) (women)
Dietary risk	Diet low in fruits, diet low in vegetables, diet low in whole grains, diet high in red meat, diet high in processed meat, diet high in sugar-sweetened beverages, diet low in fibre	
Physical activity	low physical activity (< 1.5 METs)	150 minutes; 75 min (high intensity)
V D (1		2000 N 22(11) 2122 2122

Yang B, et al. *Environ Res* (2020) Chang S et al. <u>Diabetes Metab J.</u> 2012 Dec; 36(6): 399–403. Baliunas et al. <u>Diabetes Care.</u> 2009 Nov; 32(11): 2123–2132. Chan J, et al. *Diabetes Care.* 1994;17:961-969 (hommes) Colditz G, et al. *Ann Intern Med.* 1995;122:481-486 8 (femmes)

#### Type 2 diabetes and many others



Swiss recommandations 2023

#### Inflammation and insulin resistance



Development of inflammation in T2D



Interleukin-1 $\beta$ -induced inflammation in islets of patients with T2D

Donath M. Nat Rev Immunol 11, 98–107 (2011)

#### Overview of T2D complexity



Nature reviews endocrinology, vol 10, 2014

#### Type 2 diabetes is an evolutive disease



Brownlee M. et al Nature. 2001 Dec 13;414(6865):813-20. Henry RR. Am J Med. 1998 Jul 6;105(1A):20S-26S

#### 4 major pathways of hyperglycemic damages



AGE, advanced glycation end-product; eNOS, endothelial nitric oxide synthetase; Et-1, endothelin-1; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor-β; PAI-1, plasminogen activator inhibitor-1 (PAI-1), ROS, reactive oxygen species. Adapted from Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 Dec 13;414(6865):813-20.



0 0 Monocyte Proteins  $\bigcirc$ 0  $\bigcirc$ Heparan sulfat aluron: aranase granule Endothelial Glycocalyx Endothelial Macronh ubendothelia

arteries, veins and lymphatics

Dogné S. et al. 2018 Arteriosclerosis, Thrombosis, and Vascular Biology Rabelink, T., de Zeeuw, D. *Nat Rev Nephrol* **11**, 667–676 (2015)



# Diabetes is associated with endothelial glycocalyx damages



#### Acute hyperglycemia reduce the glycolayx volume

Niewdorp M et al. Diabetes. 2006;55:480-486.

Patients with T2D have decreased endothelial glycocalyx dimensions compared with healthy controls (sublingual and retinal microcirculation; erythrocyte–endothelium gap)

Broekhuizen L.N et al. Diabetologia. 2010; 53(12): 2646–2655.

# Endothelial glycocalyx : a *shield against* diabetes related vascular complications !

Sophie Dogné et al. 2018 Arteriosclerosis, Thrombosis, and Vascular Biology.

# DmVC and Chronic Venous Disease (CVeD) have common risk factors and pathophysiology



Gastaldi G et al. Int Angiol. 2021 Dec;40(6):457-469

### CVeD (CVI) is associated with arterial cardiovascular disease and an increased risk of all-cause mortality



Eur Heart J, Volume 42, Issue 40, 21 October 2021, Pages 4157–4165







Scientific Reports volume 12, Article number: 129 (2022)

### The Taiwanese Longitudinal Health Insurance Database 2000 No, N=132,136 Yes, N=33,034



Conclusions: A significantly increased PAOD risk in patients with hemorrhoids was found in this nationwide cohort study.



Hemorrhoid patients have a 1.27-fold higher risk of CHD compared with those without hemorrhoids after adjusting for the potential confounding factors

Medicine (Baltimore). 2017 Aug; 96(31): e7662.

### Pathophysiology of complications related to DM



# ~50% of T2DM patients are developing microvascular complications (DMVCs)

#### Prevalence rates for DMVCs in T2DM patients

DR



DN

DMVC, diabetic microvascular complication; DN, diabetic nephropathy; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy

Litwak L, et al. Diabetol Metab Syndr 2013;5(1):57

6.7

Million

Deaths due to DM in 2021

10<sup>th</sup> IDF atlas

#### T2D and Cardiorenal complications



Birkeland KI et al. Diabetes Obes Metab. 2020 Sep;22(9):1607-1618.

Modified from: Retnakaran & Zinman, Lancet 2008; 371:1790-99

#### T2D Management $\rightarrow$ preventing complications



Diabetes Care 2022; https://doi.org/10.2337/dci22-0034. Diabetologia 2022; https://doi.org/10.1007/s00125-022-05787-2.



### Mode de vie





150 min

The Role of Diet and Food. Nutrients. 2023 Jan 26;15(3):640.

# Among patients with diabetes, there is a high rate of undiagnosed HF and sub-optimal GDMT

534 patients enrolled in the SwissDiab Registry at KSSG were screened for HF based on the ESC recommendations between 28.09.2020 and 31.03.2022.



#### Proportion of identified case with HF, stratified by LVEF

#### **Results:**

- HF was identified in 16% of patients with T2D.
- Of the identified cases of HF, **3 out of 5 were previously undiagnosed**, the majority **HFpEF**.
- Of the 60 patients that were identified with HF, n=19 (31.7%) were prescribed SGLT2i (HFpEF, n=7 [20.6 %]; HFmrEF, n=2 [28.6 %]; HFrEF, n=10 [52.6 %]).



Proportion of HFrEF, HFmrEF and HFpEF among previously and newly diagnosed cases of HF.

ESC: European Society of Cardiology, HF: heart failure, KSSG: Kantonsspital St. Gallen, T2D: type-2 diabetes, HFmrEF: heart failure with mildly reduced LVEF, HFrEF: heart failure with reduced LVEF, HFpEF: heart failure with preserved LVEF, LVEF: left ventricular ejection fraction.

Knaus L et al. Screening for heart failure in patients with diabetes mellitus in tertiary care - A SwissDiab study. Diabetes Res Clin Pract. 2024 Feb 7;209:111565.

#### Physiological effects of New pharmacologic options for DM

Benefits of early tight glycemic control in reducing the occurrence of micro- and macrovascular disease Blood pressure control and lipid-lowering therapy outweight glycemic control for cardiovascular prevention Cardiorenal outcome benefits with the use of new glucose-lowering d 3 years intervals, starting at age 45 rugs

BW

#### **GLP-1** (glucagon-like peptide-1)<sup>1</sup>

- ↓ Appetite (body weight)
- ↓ Glycemia
- ↑ Heart rate
- ↑ ↑ Insulin secretion
- ↓ ↓ Glucagon secretion
- ↓ ↓ Gastric emptying
- ↓ Chylomicron production
- ↓ Na excretion (transient)
- ↑ Meal-associated bone remodelling

#### **iSGLT2** (Sodium-Glucose Co-transporter 2 Inhibitor)<sup>2</sup>

- Body weight (visceral fat)
- Blood pressure
- 🔸 🛛 🗸 🗸 🗸 Glycemia

 $\mathbf{1}$ 

- ↑ Glucagon secretion
- ↑ ↑ Na excretion
  - Circulating volume
    - 1. Nauk MA et al. Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29
    - 2. Yang Y et al. Front Endocrinol (Lausanne). 2020 Apr 15;11:190.

#### Atherogenic and cardiorenal risk pathways in DM



Adapted from Sattar N. et al. Circulation 2018;138:(7-9)

#### T2D management: disease-modifying drugs



Gastaldi et al. Swiss Med Wkly. 2023;153:40060



CVeD, chronic venous disease; DmVC, Diabetic microvascular Complications; GLP-1, glucagon-like peptide-1; iSGLT2, Sodium-Glucose Co-transporter 2 Inhibitor.

#### Take home messages

Cardiovascular diseases (CVDs) are the leading cause of death globally.

People living with Type 1 and type 2 diabetes are 2 times more likely to develop and die from cardiovascular disease (heart attacks, strokes, heart failure)

Risk of DmVC and Atheromatosis after intensified therapy is still present in people with diabetes

DM related complications and pathophysiology of hemorroidal disease, and chronic venous disease **are** driven by **endothelial dysfunction due to increase of vascular inflammation, oxidative stress and VEGF<sup>2</sup>**.

**Drugs targeting the glycocalyx and** indicated **for the treatment of HD, as well as both CVI** and **DmVC** should be considered for patients with co-existing conditions.

Patients with circulatory system diseases may benefit from **new glucose lowering drugs (iSGLT2 and GLP-1a)**<sup>8,9</sup> as well as from **drugs targeting the glycocalyx matrix.** 

\*Based on brands from the Swiss market (https://compendium.ch/product/19768-doxium-caps-500-mg/product) CVeD, chronic venous disease; CVI, chronic venous insufficiency, DmVC, Diabetic microvascular Complications; GLP-1, glucagon-like peptide-1; iSGLT2, Sodium-Glucose Co-transporter 2 Inhibitor; VEGF, vascular endothelial growth factor. References : see note section



### Thank you for your attention!

### Questions?